Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 4/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633935 | 0.90 | ADRA1A (0.44) | ADRA1ACYP11B1CYP11B2KDM4EALDH1A1 | |
| SCHEMBL28212021 | 0.87 | ADRA1A (0.51) | ADRA1AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL6383642 | 0.87 | ADRA1A (0.51) | ADRA1AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL161548 | 0.87 | ADRA1A (0.51) | ADRA1AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL17185046 | 0.85 | PARP1 (0.55) | ADRA1AKDM4EALDH1A1PARP1 | |
| Hydrochloric Acid SCHEMBL30170745 | 0.85 | ADRA1A (0.50) | ADRA1AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL31748898 | 0.85 | CYP11B1 (0.43) | CYP11B1CYP11B2KDM4EALDH1A1PARP1 | |
| SCHEMBL730750 | 0.84 | CYP2C9 (0.49) | KDM4EALDH1A1MAPTHPGDKAT2B | |
| SCHEMBL20822490 | 0.84 | PARP1 (0.43) | CYP11B1CYP11B2PARP1KAT2BBAZ2B | |
| SCHEMBL161226 | 0.84 | KDM4E (0.50) | ADRA1AKDM4EALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4274825-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| EP-4263546-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-10-25 | — | — | EP | claimed |
| WO-2022150381-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2022-07-14 | — | — | WO | claimed |
| WO-2022128851-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-23 | — | — | WO | claimed |
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | claimed |
| EP-2321308-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | claimed |
| EP-1021411-A1 | BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-07-26 | — | — | EP | claimed |
| WO-1997022589-A1 | BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS | GLAXO GROUP LIMITED (GB) | 1997-06-26 | — | — | WO | claimed |
| US-20250074906-A1 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-06 | — | — | US | disclosed |
| EP-4384510-A1 | COMPOUNDS TARGETING MUTANT OF P53 | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024078118-A1 | CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024078119-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2024-04-18 | — | — | WO | disclosed |
| US-20240092792-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-21 | — | — | US | disclosed |
| EP-4320223-A1 | CHEMICAL REPROGRAMMING OF HUMAN SOMATIC CELLS INTO PLURIPOTENT CELLS | Peking University (CN) | 2024-02-14 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| EP-2349260-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | Incyte Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2303889-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010039939-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-1021411-A1 | BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-07-26 | — | — | EP | disclosed |
| WO-1997022589-A1 | BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS | GLAXO GROUP LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074906-A1 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | HPGDS, PTGIS, HPGD | ADRA1A 1769/4885CYP11B1 102/4885CYP11B2 87/4885 |
| US-20240092792-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | ADRA1A 459/4885CYP11B1 198/4885CYP11B2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.